Godiva ordered by Hong Kong govt to halt dark chocolate ice cream sale after bacteria find
The Centre for Food Safety said on Thursday that the sample collected from the shop at Cityplaza in Tai Koo had 2.3 million bacteria per gram – 46 times higher than the legal limit of 50,000.
'The centre has informed the vendor involved of the irregularity and instructed it to stop selling and immediately dispose of the affected product,' a spokesman said. 'Prosecution will be instituted should there be sufficient evidence.'
Under the Frozen Confections Regulation, those convicted of selling frozen confections with bacterial levels exceeding the legal limit face a maximum penalty of a fine of HK$10,000 (US$1,273) and three months' imprisonment.
The spokesman said the centre had asked Godiva to carry out a thorough cleaning and disinfection.
He added that the centre had also provided health education on food safety and hygiene to the vendor's representative and staff.
The centre also noted that the total bacterial count exceeding the legal limit indicated unsatisfactory hygienic conditions, but that did not mean that consumption would lead to food poisoning. - SOUTH CHINA MORNING POST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
9 hours ago
- The Sun
AstraZeneca plans US$50b US move amid tariff threat
WASHINGTON: AstraZeneca plans to spend US$50 billion (RM212 billion) to expand manufacturing and research capabilities in the US by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach US$80 billion in annual revenue by 2030, with half coming from the US. The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market – the world's largest, worth US$635 billion – before Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The US cannot build or carry the cost of R&D for the entire world,' he said. US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the US$3.5 billion in investments the company announced in November 2024, the statement said. The US$50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson , Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility – the company's largest single manufacturing investment – will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. – Reuters
The Star
14 hours ago
- The Star
Indonesia seizes record US$590mil in meth, uncovers maritime drug route in South-East Asia
JAKARTA: Indonesia is on track to record the largest seizure of drugs by the National Narcotics Agency (BNN) in six years, said the agency's chief, with confiscation of methamphetamine reaching 3.41 tonnes – with a street value of US$590 million – so far in 2025. This half-year haul has surpassed the total annual seizure in the previous five years. The latest raid in the waters off Batam in mid-May netted a record 2.1 tonnes of methamphetamine, a synthetic drug also known as meth. The amount can feed eight million addicts, with each gram typically consumed by four people. BNN confiscated less than a tonne for the whole of 2024, and between 2020 and 2023, annually netted between 1.2 tonnes and 2.8 tonnes, according to government data. Government agencies have also, so far in 2025, seized 2.65 tonnes of other drugs, such as marijuana and cocaine, with a street value of at least $95 million. In an interview on July 3, BNN chief Marthinus Hukom shed light on a drug-trafficking maritime route spanning Malaysia, the Philippines and Taiwan. 'The production was in Myanmar while the vessel was built in Thailand,' said Commissioner-General Marthinus, referring to the meth seizure in May. Large-scale production of meth, combined with an ongoing war in Myanmar since 2021, has driven up the supply of the illicit drug in South-east Asia, said a recent report by the UN Office on Drugs and Crime (UNODC). Seizures of meth across the region were at record highs in 2024, totalling 236 tonnes – a 24 per cent increase compared with the 2023 haul, said UNODC. Meth, a powerful and fast-acting stimulant, can harm a person's heart, teeth and brain if used regularly. It can also cause paranoia, mood swings and memory loss. While there has been a slight decline in drug prevalence in Indonesia, it is still at a worrying level. Marijuana and meth are the two most-used drugs, followed by Ecstasy, ketamine, cocaine and prescription drug abuse. The number of police cases involving arrests of drug offenders in the first 11 months of 2024 stood at 53,672 – up from 50,291 cases in 2023, and 44,983 in 2022, according to government data. Marthinus revealed that for the large meth seizure in May, the drugs had been loaded onto a trade ship in the Andaman Sea off Myanmar. The vessel, Sea Dragon Tarawa, then sailed south through the Malacca Strait to the waters bordering Indonesia and Singapore. It later turned into the South China Sea, cruising off Kalimantan to drop off the meth packages for the Indonesian market, he said. The ship then headed into Philippine and Taiwan waters to unload more drugs. It later looped back to go back into the Andaman Sea, with the trip made several times. It was during one of those regular trips that the ship was caught near Batam, after leaving the Malacca Strait. Data of the trips made was collected by BNN from the vessel's Automatic Identification System satellites. Noting that drug packages sometimes fall off a vessel during trans-shipment, Marthinus said: 'Small boats pick up merchandise from the passing vessel. In the past, local fishermen have found drug packages floating on the sea off North Kalimantan.' The drugs dropped off near Kalimantan were taken to Java and Sulawesi, among other places. According to BNN's analysis, the drugs normally enter Malaysia via boats from Sarawak's capital Kuching and the Philippines through Tawi-Tawi and Mindanao islands. Singapore was not on the delivery list of the Sea Dragon Tarawa. 'We have cut the trade chain for not only Asean countries, but also Taiwan. We expect the drug rings will change their route,' said Marthinus, a former head of Indonesia's anti-terror police squad Detachment 88. Meth in Indonesia is commonly consumed by labourers, plantation workers, drivers and nightlife workers, while marijuana is typically favoured by youth and students. Another synthetic drug, Ecstasy, is commonly used in nightclubs, said BNN. Maturidi Putra, a former drug addict who has been clean for 10 years, said: 'The cure is as simple as returning to the life we had before we became addicted. Avoid the people and environment that led us there in the first place.' The 51-year-old entrepreneur is among scores of people who have returned to a normal life without going through rehabilitation. Denny Bintang, 39, an anti-drug activist who started a 6,400-member Facebook group promoting rehabilitation and campaigning against illicit drugs, told The Straits Times that many addicts are unaware of government facilities that offer free rehabilitation services. 'Many are also afraid to come forward and use the service, thinking they will be arrested,' said Denny, noting there is low awareness that Indonesian law recognises some users as victims, not criminals. He also noted that privately run rehabilitation centres are expensive and not every addict or the family can afford it. The average retail price of meth in Indonesia in 2024 was about US$135 (S$173) per gram, according to UNODC. Prices vary widely across the region, with the lowest prices reported near Myanmar and rising in places farther away. The per-gram street price is US$6 in Myanmar, US$79 in the Philippines, and US$68 in Hong Kong, the UN agency said in a June 26 report. The May raid on the Sea Dragon Tarawa was the result of a five-month intelligence operation, Marthinus said. The six-member crew – four Indonesians and two Thais – were arrested, and 67 cardboard boxes, wrapped in plastic and camouflaged as green tea packages, were seized as evidence. Inside the boxes were 2,000 smaller packages of meth weighing a total of 2.1 tonnes. Similar to a terror network, drug ring leaders target people from poor economic backgrounds to help them expand operations as they are easy to recruit, said Marthinus. 'In the drug operations, they are the sales agents, couriers... We map out the regions in Indonesia that are prone to be recruitment centres. We do our work from there,' he added. Meanwhile, the total number of drug abusers remains a worry, even though the figure has dipped slightly. Indonesian government data shows drug users in the 15 to 64 age group totalled 3.33 million people in 2023, compared with 3.66 million in 2021. Yogo Tri Hendiarto, a criminologist at the University of Indonesia, told ST: 'Demand dictates supply. The large quantity of drugs confiscated this year suggests that demand remains strong in Indonesia and elsewhere, while the country's low prevalence rate indicates that prevention and rehabilitation efforts have been effective.' But he noted that the lower number of drug abusers could be due to weaknesses in survey methodology. - The Straits Times/ANN
New Straits Times
20 hours ago
- New Straits Times
AstraZeneca unveils US$50bil investment as pharma tariff threat looms
WASHINGTON: AstraZeneca plans to spend US$50 billion to expand manufacturing and research capabilities in the US by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach US$80 billion in annual revenue by 2030, with half coming from the US. The US accounted for more than 40 per cent of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market – the world's largest, worth US$635 billion – before Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and "equalise" with other countries effectively contributing more to research and development costs. "The United States cannot build or carry the cost of R&D for the entire world," he said. US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any levies take effect. The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the US$3.5 billion in investments the company announced in November 2024, the statement said. Pledges The US$50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility – the company's largest single manufacturing investment – will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. In January, it scrapped plans to invest £450 million (US$607.10 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London – where it is the exchange's most valuable company worth £159 billion – to the US. The company declined to comment.
